HIV-1 vaccine antibody induction against a variable region of HIV-1

A possible link to protective immunity?

Research output: Contribution to journalArticle

Abstract

Evaluation of: Liao H, Bonsignori M, Alam M et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186 (2013). In 2009, results from the Phase III HIV-1 vaccine clinical trial RV144 applying a prime/boost regimen with a canarypox vaccine vector ALVAC-HIV plus the AIDSVAX B/E subunit envelope vaccine conducted in Thailand were reported. The priming canarypox vector carried the HIV-1 vaccine genes gp120 linked to the transmembrane-anchoring portion of subtype B gp41, HIV-1 Gag and protease; the boosting vaccine was composed of clades B and E of HIV-1 gp120. A 31.2% vaccine efficacy could be seen in this trial, an encouraging result in HIV-1 vaccine research that had been previously plagued with little clinical efficacy. In this paper, results from tests of four monoclonal antibodies isolated from RV144 vaccinees are reported. The antibodies recognize a certain HIV-1 envelope residue (169), neutralize laboratory-adapted HIV-1 strains and mediate killing of CD4+ cells infected with HIV-1 laboratory isolates. Crystal structure analysis suggests that the recognized HIV-1 envelope epitope can exist in different conformations. It is thought that the immune pressure elicited by the monoclonal antibodies targets a HIV-1 envelope region with variable sequence structure.

Original languageEnglish (US)
Pages (from-to)453-455
Number of pages3
JournalImmunotherapy
Volume5
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

AIDS Vaccines
HIV-1
Immunity
Antibodies
Vaccines
HIV Envelope Protein gp41
Monoclonal Antibodies
Pressure
Subunit Vaccines
Thailand
Epitopes
Clinical Trials

Keywords

  • antibodies against variable region of HIV-1
  • broadly neutralizing antibodies
  • CH58 and CH59 antibodies
  • gp120 antibodies
  • HIV-1 vaccine
  • protective immunity
  • RV144 clinical trial

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

HIV-1 vaccine antibody induction against a variable region of HIV-1 : A possible link to protective immunity? / Bauer, Gerhard.

In: Immunotherapy, Vol. 5, No. 5, 05.2013, p. 453-455.

Research output: Contribution to journalArticle

@article{134e8cfbe1414fa9bf941490c8aff7bf,
title = "HIV-1 vaccine antibody induction against a variable region of HIV-1: A possible link to protective immunity?",
abstract = "Evaluation of: Liao H, Bonsignori M, Alam M et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186 (2013). In 2009, results from the Phase III HIV-1 vaccine clinical trial RV144 applying a prime/boost regimen with a canarypox vaccine vector ALVAC-HIV plus the AIDSVAX B/E subunit envelope vaccine conducted in Thailand were reported. The priming canarypox vector carried the HIV-1 vaccine genes gp120 linked to the transmembrane-anchoring portion of subtype B gp41, HIV-1 Gag and protease; the boosting vaccine was composed of clades B and E of HIV-1 gp120. A 31.2{\%} vaccine efficacy could be seen in this trial, an encouraging result in HIV-1 vaccine research that had been previously plagued with little clinical efficacy. In this paper, results from tests of four monoclonal antibodies isolated from RV144 vaccinees are reported. The antibodies recognize a certain HIV-1 envelope residue (169), neutralize laboratory-adapted HIV-1 strains and mediate killing of CD4+ cells infected with HIV-1 laboratory isolates. Crystal structure analysis suggests that the recognized HIV-1 envelope epitope can exist in different conformations. It is thought that the immune pressure elicited by the monoclonal antibodies targets a HIV-1 envelope region with variable sequence structure.",
keywords = "antibodies against variable region of HIV-1, broadly neutralizing antibodies, CH58 and CH59 antibodies, gp120 antibodies, HIV-1 vaccine, protective immunity, RV144 clinical trial",
author = "Gerhard Bauer",
year = "2013",
month = "5",
doi = "10.2217/imt.13.32",
language = "English (US)",
volume = "5",
pages = "453--455",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - HIV-1 vaccine antibody induction against a variable region of HIV-1

T2 - A possible link to protective immunity?

AU - Bauer, Gerhard

PY - 2013/5

Y1 - 2013/5

N2 - Evaluation of: Liao H, Bonsignori M, Alam M et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186 (2013). In 2009, results from the Phase III HIV-1 vaccine clinical trial RV144 applying a prime/boost regimen with a canarypox vaccine vector ALVAC-HIV plus the AIDSVAX B/E subunit envelope vaccine conducted in Thailand were reported. The priming canarypox vector carried the HIV-1 vaccine genes gp120 linked to the transmembrane-anchoring portion of subtype B gp41, HIV-1 Gag and protease; the boosting vaccine was composed of clades B and E of HIV-1 gp120. A 31.2% vaccine efficacy could be seen in this trial, an encouraging result in HIV-1 vaccine research that had been previously plagued with little clinical efficacy. In this paper, results from tests of four monoclonal antibodies isolated from RV144 vaccinees are reported. The antibodies recognize a certain HIV-1 envelope residue (169), neutralize laboratory-adapted HIV-1 strains and mediate killing of CD4+ cells infected with HIV-1 laboratory isolates. Crystal structure analysis suggests that the recognized HIV-1 envelope epitope can exist in different conformations. It is thought that the immune pressure elicited by the monoclonal antibodies targets a HIV-1 envelope region with variable sequence structure.

AB - Evaluation of: Liao H, Bonsignori M, Alam M et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186 (2013). In 2009, results from the Phase III HIV-1 vaccine clinical trial RV144 applying a prime/boost regimen with a canarypox vaccine vector ALVAC-HIV plus the AIDSVAX B/E subunit envelope vaccine conducted in Thailand were reported. The priming canarypox vector carried the HIV-1 vaccine genes gp120 linked to the transmembrane-anchoring portion of subtype B gp41, HIV-1 Gag and protease; the boosting vaccine was composed of clades B and E of HIV-1 gp120. A 31.2% vaccine efficacy could be seen in this trial, an encouraging result in HIV-1 vaccine research that had been previously plagued with little clinical efficacy. In this paper, results from tests of four monoclonal antibodies isolated from RV144 vaccinees are reported. The antibodies recognize a certain HIV-1 envelope residue (169), neutralize laboratory-adapted HIV-1 strains and mediate killing of CD4+ cells infected with HIV-1 laboratory isolates. Crystal structure analysis suggests that the recognized HIV-1 envelope epitope can exist in different conformations. It is thought that the immune pressure elicited by the monoclonal antibodies targets a HIV-1 envelope region with variable sequence structure.

KW - antibodies against variable region of HIV-1

KW - broadly neutralizing antibodies

KW - CH58 and CH59 antibodies

KW - gp120 antibodies

KW - HIV-1 vaccine

KW - protective immunity

KW - RV144 clinical trial

UR - http://www.scopus.com/inward/record.url?scp=84877246287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877246287&partnerID=8YFLogxK

U2 - 10.2217/imt.13.32

DO - 10.2217/imt.13.32

M3 - Article

VL - 5

SP - 453

EP - 455

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 5

ER -